Search

Displaying results 6191 - 6200 of 8469 in total
  1. Drug

    Evodenoson

    go.drugbank.com/drugs/DB12295
    Investigational

    Evodenoson has been used in trials studying the treatment of Open-angle Glaucoma and Ocular Hypertension.

  2. Drug

    Perzinfotel

    go.drugbank.com/drugs/DB12365
    Investigational

    Perzinfotel has been used in trials studying the treatment of Diabetes Mellitus and Diabetic Neuropathy, Painful.

  3. Drug

    OSI-027

    go.drugbank.com/drugs/DB12387
    Investigational

    OSI-027 has been used in trials studying the treatment of Any Solid Tumor or Lymphoma.

  4. Drug

    Ketanserin

    go.drugbank.com/drugs/DB12465
    Investigational

    Ketanserin has been investigated for the treatment of Septic Shock, Severe Sepsis, and Diabetic Foot Ulcer.

  5. Drug

    BI-671800

    go.drugbank.com/drugs/DB12524
    Investigational

    Bi 671800 has been used in trials studying the treatment of Asthma and Rhinitis, Allergic, Perennial.

  6. Drug

    MK-0686

    go.drugbank.com/drugs/DB12563
    Investigational

    MK0686 has been used in trials studying the treatment of Osteoarthritis, Pain, Postoperative, and Neuralgia, Postherpetic.

  7. Drug

    Senrebotase

    go.drugbank.com/drugs/DB12626
    Investigational

    Senrebotase has been used in trials studying the treatment of Neuralgia, Postherpetic and Urinary Bladder, Overactive.

  8. Drug

    Neflamapimod

    go.drugbank.com/drugs/DB07138
    Investigational

    Neflamapimod has been used in trials studying the treatment of Alzheimer's Disease and Mild Cognitive Impairment.

  9. Drug

    Irosustat

    go.drugbank.com/drugs/DB02292
    Investigational

    Irosustat has been investigated for the treatment of Metastatic Breast Cancer and Locally Advanced Breast Cancer.

  10. Drug

    RESP301

    go.drugbank.com/drugs/DB16497
    Investigational

    RESP301 was under investigation in clinical trials for various conditions. … It was studied in community patients at risk of viral infections, including SARS-CoV-2, in a terminated trial (NCT04858451) and adults with rifampicin-susceptible pulmonary tuberculosis in a recruiting